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Abstract White matter disorders (WMDs) are a major source
of handicap at all ages. They often lead to progressive neuro-
logical dysfunction and early death. Although causes are highly
diverse, WMDs share the property that glia (astrocytes and
oligodendrocytes) are among the cells primarily affected, and
that myelin is either not formed or lost. Many WMDs might
benefit from cell replacement therapies. Successful preclinical
studies in rodent models have already led to the first clinical
trials in humans using glial or oligodendrocyte progenitor cells
aiming at (re)myelination. However, myelin is usually not the
only affected structure. Neurons, microglia, and astrocytes are
often also affected and are all important partners in creating the
right conditions for proper white matter repair. Composition of
the extracellular environment is another factor to be considered.
Cell transplantation therapies might therefore require inclusion
of non-oligodendroglial cell types and target more than only
myelin repair. WMD patients would likely benefit from multi-
modal therapy approaches involving stem cell transplantation
and microenvironment-targeting strategies to alter the local
environment to a more favorable state for cell replacement.
Furthermore most proof-of-concept studies have been per-
formed with human cells in rodent disease models. Since
human glial cells show a larger regenerative capacity than their
mouse counterparts in the host mouse brain, microenvironmen-
tal factors affecting white matter recovery might be overlooked
in rodent studies. We would like to stress that cell replacement
therapy is a highly promising therapeutic option forWMDs, but
a receptive microenvironment is crucial.
BLeukoencephalopathies^ or Bwhite matter disorders^ (WMDs)
are all disorders that predominantly or exclusively affect the
brain white matter. They can be inherited or acquired.
Common acquired WMDs are multiple sclerosis (MS; inci-
dence 1:1000) and periventricular leukomalacia (PVL; inci-
dence 1:1800). The genetic leukoencephalopathies, collectively
called the Bleukodystrophies^, include several inborn errors of
metabolism. They mainly affect children and often cause pro-
gressive white matter destruction and loss, leading to severe
disabilities and early death. This group of disorders consists of
many rare to extremely rare disorders, but as a group the inci-
dence is unexpectedly high, estimated at ~1:7000 live births
(Bonkowsky et al 2010). In patients with leukodystrophies the
white matter of the central nervous system (CNS) is affected,
with or without peripheral nervous system involvement, based
on glial cell or myelin sheath abnormalities (Vanderver et al
2015). Better treatment is urgently needed forWMDs at all ages.
Glia replacement therapies have great prospects for WMDs,
especially for the leukodystrophies as these are caused by a
genetic defect, which is not present in the transplanted cells.
White matter consists of myelin, oligodendrocytes, axons,
astrocytes, and microglial cells. Myelin protects the health of
axons and increases the speed and efficiency of neuronal
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conductance. In the CNS, the oligodendrocytes are responsible
for myelin formation, while astrocytes have many homeostatic
functions including supporting the formation and maintenance
of myelin. In WMDs different cells or structures may be pri-
marily or secondarily involved. Mutations in the proteolipid
protein 1 (PLP1), a predominant myelin protein, are associated
with X-linked Pelizaeus-Merzbacher disease (PMD; OMIM
#312080) and affect the compactness of myelin and maturation
of oligodendrocytes. Other WMDs are caused by mutations in
genes predominantly expressed in astrocytes. A typical exam-
ple is Alexander disease (OMIM #203450), a progressive leu-
kodystrophy, caused by mutations in the GFAP gene (Messing
et al 2010). Also, megalencephalic leukoencephalopathy with
subcortical cysts (MLC; OMIM #604004) is caused by lack of
the astrocyte-specific MLC1 protein, either through mutations
in theMLC1 gene (73 %) or in theGLIALCAM gene, encoding
the MLC1 chaperone GlialCAM (20 %), which ensures proper
localization at astrocytic endfeet (Dubey et al 2015). Autopsies
of patients with WMDs not only reveal lack of myelin and
astrogliosis, but also axonal and neuronal degeneration.
Examples are the widespread affected axonal integrity in pa-
t i en t s w i th 4H (hypomye l ina t ion , hypodon t i a ,
hypogonadotropic hypogonadism) leukodystrophy
(Vanderver et al 2013) (OMIM #614381) and the neuroaxonal
degeneration in patients with PMD (Garbern et al 2002).
Microglial cell involvement is illustrated byMSwhere microg-
lia activation contributes to inflammatory demyelination and
neurodegeneration (Mahad et al 2015). Interestingly many
WMDs are caused by genes which are ubiquitously expressed
by all cells. Vanishing white matter disease (VWM; OMIM
#603896) is one of the most prevalent genetic childhood
WMDs, caused by mutations in any of the five subunits of
eukaryotic translation initiation factor eIF2B. Although eIF2B
is involved in all cells of our body, autopsies indicate predom-
inant involvement of the oligodendrocytic and astrocytic cell
types (Bugiani et al 2013). Recent studies confirm a major role
for astrocyte dysfunction in VWM (Dooves et al 2016). Since
WMDs show changes in the astrocyte and oligodendrocyte
populations, and because their progenitors have migrative and
plastic properties, they are attractive candidates for glial cell
replacement therapy. Of note, white matter abnormalities have
also been appreciated in a number of neurodegenerative dis-
eases traditionally viewed as primary neuronal disorders.
Examples are the toxicity of astrocytes in amyotrophic lateral
sclerosis (Meyer et al 2014) and problems with white matter
connectivity in schizophrenia (Landek-Salgado et al 2015).
Because glia contributions are recognized, at least in a subset
of neuronal disorders, glial-targeted therapy strategies for these
disorders have been suggested as well.
In the design of cell replacement therapy, the complexity of
white matter should be considered, as all components of the
white matter microenvironment potentially impact the integ-
rity of the white matter and the survival or functioning of
(transplanted) cells. The microenvironment is defined as the
local environment in the brain or in a specific brain region, and
consists of (neural and non-neural) cells, the extracellular ma-
trix (ECM), blood derived factors and factors provided by
cells. The microenvironment is defined according to a certain
point of reference, e.g., the microenvironment of white matter
oligodendrocytes and myelin is everything in the local envi-
ronment, potentially impacting these cells and the myelin. The
composition of the microenvironment is often changed in dis-
ease. Since neurons, microglia, and astrocytes are all impor-
tant partners in creating the right microenvironment for mye-
lin maintenance and repair, cell transplantation strategies
might require, at least in a subset of WMDs, inclusion of
non-oligodendroglial cell types.
So, we argue that white matter repair therapies, next to glia
replacement, should also involve strategies targeting the mi-
croenvironment to make it sufficiently receptive for
transplanted cells.
A number of successful cell replacement therapies have
been performed in rodent models of hypomyelinating diseases,
suggesting the feasibility of such strategies in human subjects.
The most commonly used model is the shiverer mouse, which
has a major deletion in the myelin basic protein gene (MBP).
The homozygous shiverer mutants present with a shivering
phenotype, tonic seizures, and have a life span of 14–21 weeks
depending on modulating factors like an immunodeficient
background (Uchida et al 2012). Histology reveals myelin de-
ficiency. It has proven to be possible to rescue the phenotype of
immunodeficient shiverer mice by injecting human glial pro-
genitor cells (Windrem et al 2008). This has led to the first
early-phase clinical trial to test safety of neural stem cells and
to identify proof of myelination after transplantation. Four male
patients with an early-onset severe form of PMD were injected
with clinical-grade human CNS stem cells (HuCNS-SCs). At a
1 year follow-up, the results assure safety and suggest prelim-
inary efficacy (Gupta et al 2012). The authors report that pa-
tients showed stable to minor gains in neurological function
after transplantation, and that the imaging studies give signals
that could indicate myelination in transplanted regions.
Although it is expected that the numbers of cells transplanted
were too low to obtain considerable improvements, the authors
suggested that immunosuppressive agents might also have
inhibited myelination by donor cells. This underscores the im-
portance of modulating the microenvironment into a receptive
state in order to obtain successful cell replacement. This first
clinical report encourages the continuation of investigation of
cell replacement therapies to achieve white matter repair, with
an initial focus on leukodystrophies.
Since factors secreted by astrocytes or microglia play an im-
portant role in oligodendrocyte functioning in both health and
disease (Boulanger and Messier 2014), cell replacement might
fail to remove adverse elements in the diseased host microenvi-
ronment threatening the success of myelin repair. For example,
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studies have shown that in MS lesion sites the inflammatory
environment can inhibit neural progenitor cell survival
(Giannakopoulou et al 2011), and that residing reactive astro-
cytes secrete growth factors like FGF2 and BMPs, and ECM
components like hyaluronan that can inhibit oligodendrocyte
maturation (Moore et al 2011). Globoid cell leukodystrophy, or
Krabbe disease (OMIM #245200), is caused by deficiency of
galactocerebrosidase (GALC; EC: 3.2.1.46). Deficiency of
GALC leads to accumulation of galactosylceramide and its toxic
derivative psychosine in oligodendrocytes and subsequently to a
more generally increased psychosine level in the brain.
Oligodendrocytes are sensitive to psychosine and die, but the
increased psychosine levels also affect other cells like microglia.
A cell replacement study with healthy oligodendrocyte progen-
itor cells, which are resistant to psychosine toxicity, most likely
failed due to the die-off of donor cells the moment they matured
into MBP-positive psychosine-sensitive oligodendrocytes (Kuai
et al 2015). Furthermore, a recent study by Sekiya et al (2015),
investigating the effects of transplantation of neuroblast cells
after nerve injury, showed the importance of injection site of
the transplant. The authors showed that cells injected on top of
the damaged nerve were able to enter the damaged nerve tissue
and cause functional recovery, while cells directly injected into
the damaged area did not survive. These studies illustrate that the
microenvironment can have amajor impact on the success of cell
replacement. Therefore modulation of the diseased microenvi-
ronment and specific localization of cells need careful consider-
ations while designing cell transplantation therapies (Fig. 1).
Cell transplantation is not always aimed at replacing affected
cells, but practiced to modulate the microenvironment to im-
prove glia maturation and white matter repair. This is shown by
transplantation studies in the experimental autoimmune en-
cephalomyelitis (EAE) animal models for MS, which demon-
strated that the grafted cells did not participate directly in
myelination, but instead released immunomodulatory and neu-
rotrophic factors that improved the disease symptoms
(Pluchino et al 2009). This is also illustrated by strategies in-
volving non-neural cell types such as hematopoietic (HSC) or
mesenchymal (MSC) stem cells. HSC transplantation has been
used in clinics for over 30 years and is optional for some
WMDs. After grafting, HSCs differentiate into monocytes, mi-
grate throughout the body and become microglial cells in the
brain. Although HSCs do not differentiate into oligodendro-
cytes, HSC-derived microglial cells can provide the missing
enzymes to resident oligodendrocytes and can remove inhibi-
torymyelin debris in the microenvironment, thereby slowing or
halting disease progression. For example in patients with early-
stage cerebral X-linked adrenoleukodystrophy (OMIM
#300100) and metachromatic leukodystrophy (OMIM
#604004) HSC transplantation improved the white matter ab-
normalities (Miller et al 2011; Boucher et al 2015). However,
HSC transplantations have a significant risk in developing
graft-versus-host disease. Since MSCs lack HLA class II
antigens and therefore are resistant to graft-versus-host disease,
MSC transplantation might provide a better treatment option
than HSCs (Le Blanc et al 2003). MSCs, derived from bone
marrow or umbilical cord blood, are shown to inhibit autoim-
mune attacks on the CNS, secrete neurotrophic factors, recruit
oligodendrocytes and neural progenitor cells to lesion sites and/
or modulate microglia activation to a more protective pheno-
type (Uccelli et al 2011). Although HSC or MSC transplanta-
tions have especially clear prospects for WMDs involving en-
zyme deficiencies or autoimmunity, they can also support gen-
eral mechanisms involved in myelin repair.
An important part of the microenvironment is the ECM. The
ECM is composed of fibrous proteins and glycosaminoglycans
(GAGs) which are produced locally by different neural cell types
and secreted into the extracellular space were they form a dense
network and give structural support. The composition of the
ECM is dynamic and is a source for molecular signals that influ-
ence many processes like development and neuronal signaling
(Lau et al 2013). The ECMhas a strong influence on the response
of glial cells to brain damage and can promote or inhibit repair
mechanisms. This is shown in MS, where altered expression of
ECM proteins is thought to inhibit oligodendrocyte progenitor
cell maturation and myelin repair (Lau et al 2013). It is expected
that inmanyWMDs the ECM is altered as a consequence of glial
dysfunction. Recent studies show that the ECM component
hyaluronan is increased in the brains of VWM patients
(Bugiani et al 2013) and Tenascin-C production is increased in
the brains of patients with Krabbe disease (Claycomb et al 2014).
As the ECM can be crucial for the survival, integration, and
maturation of cells after transplantation, we need better under-
standing of WMD-specific changes in the ECM. Enzymatic
clearance of negative ECM components has been shown to im-
prove recovery after spinal cord injury in rodentmodels (Lau et al
2013). For diseases that involve multifocal lesions, diminishing
the inhibitory ECM components already at the production stage
might be more favorable, as shown in the lysolecithin mouse
model of demyelination (Lau et al 2013). Other potential strate-
gies can involve promotion of positive ECM components or
inhibition of receptors for ECM components, although these
await in vivo testing. ECM targeting interventions will likely be
part of future therapy approaches for WMDs.
It is expected that many WMDs will benefit from combi-
national therapies involving stem cell transplantation and mi-
croenvironment targeting strategies. Several studies using ei-
ther in vivo or in vitro methods addressed microenvironmental
factors in WMDs. For spinal cord injury, in vivo modulation
of the injection site environment using bioscaffolds containing
growth factors showed increased survival of donor cells and
functional recovery compared to transplants of cells alone or
cells on bioscaffolds without growth factors (Johnson et al
2010). Others suggested to push resident microglia to a
remyelination-supportive phenotype in MS (Olah et al
2012). A large range of co-cultures or conditioned medium
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experiments which model aspects of oligodendrocyte survival
and functioning, including the influence of other cell types,
has recently been reviewed by (Barateiro and Fernandes
2014). In vitro assays give the possibility to test positive and
negative environmental factors and suggested interventions in
higher throughput than in vivo studies. Prospects for multi-
modal therapies have recently been explored for Krabbe dis-
ease (Ricca et al 2015). The authors treated a mouse model for
Krabbe disease with either neural stem cell transplantation or
intracerebral gene therapy, followed by HSC transplantation.
Control mice were untreated or received only one of the treat-
ments. Both neural stem cell transplantation and intracerebral
gene therapy decreased the levels of toxic psychosine in the
brain, which allowed the transplanted HSCs more time to
integrate. Although all treated mice showed improvement
over the untreated mice, those that received multimodal treat-
ment showed the largest improvement.
The existence of representative disease models to test the
transplantation and modulations of the microenvironment in
vivo will be crucial. Many of the current proof-of-concept
studies for cell replacement therapies for leukodystrophies
are performed in animal models modeling myelin defects
(e.g., Shiverer mouse), but not a human disorder. To success-
fully design transplantation strategies tailored to each disease,
we need animal models which representatively mimic human
disease. Recently we have developed mouse models
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Fig. 1 Considerations in the development of cell replacement therapy. To
develop cell replacement therapy it is essential to consider the
microenvironment that donor cells encounter after transplantation.
Negative microenvironmental factors need to be considered (left side of
the figure); these can be investigated in vitro using, e.g., co-cultures or
conditioned medium experiments or in vivo by for example
immunostainings for ECM components or RNA/protein analysis. If mi-
croenvironmental components are hypothesized to have a negative influ-
ence on donor cells, they need to be modulated for cell replacement
therapy to be successful. The right side of the figure represents the cellular
studies that are needed; is it possible to obtain or make the affected cell
type in vitro, and will these cells survive and integrate after transplanta-
tion? Currently, most studies are focused on this part of therapy develop-
ment. When appropriate cells and microenvironmental modulating strat-
egies are developed, they can be combined in a multimodal therapy in
disease-specific models. In this stage it is important to consider if brain
cells are really needed or if HSC or MSC transplantation might provide a
better option. Human cell populations need to be tested in vivo to asses
their functionality, but it is also important to test same-species transplan-
tation to see the efficacy of the cell replacement therapy without the
phylogenic advantage of human donor cells
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representative for the leukodystrophies MLC (Dubey et al
2015) and VWM (Dooves et al 2016).
Another critical consideration involving the microenviron-
ment is the performance of same (allo-) or different species
(xeno-) transplantations. Human glial cells can be markedly
different from their rodent counterparts, e.g., astrocytes. Nine
months after transplantation of human glial progenitor cells
(GPCs) in both shiverer and WT mouse models, all GPCs in
the mouse are of human origin (Windrem et al 2014). By
contrast, WT mouse GPCs injected in the brains of shiverer
mice do not have the ability to outcompete host GPCs and do
not show the same migration capacity as the human GPCs
(Windrem et al 2014). If human glial cells have this large
phylogenetic advantage over rodent cells, it might also make
them less susceptible to factors released in the (diseased) mi-
croenvironment. The number of studies using rodent cells for
transplantation is small, and although most of those studies
show integration and myelination of donor cells, very few
show a rescue of the phenotype (Kuai et al 2015;
Giannakopoulou et al 2011; Plemel et al 2011). Therefore, in
order to have a more accurate estimation about the prospects
for cell replacement therapy, it would be best to test the im-
provement of the phenotype with both rodent and human
cells, to avoid overlooking microenvironmental factors in pre-
clinical studies.
In conclusion, WMDs show white matter changes involving
myelin, oligodendrocytes, astrocytes, microglia, and/or axons.
Nevertheless, a large group of WMDs will benefit from trans-
plantation of a competent glial progenitor population that is ca-
pable of migration, successful integration, and differentiation
into astrocytes and/or myelinogenic oligodendrocytes. Over time
many viable populations of human glial progenitor cells have
been developed, either derived from fetal tissue or from patient-
derived pluripotent stem cells. The development of new repre-
sentative animal models for WMDs will facilitate the investiga-
tion of environmental factors of importance to the development
of optimal transplantation strategies for every specific disease.
When the microenvironment is taken into account, cell trans-
plantation is a very promising therapeutic option for WMD!
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